Tesaro grants Zai rights to niraparib in China

Tesaro Inc. (NASDAQ:TSRO) granted Zai Lab Ltd. (Shanghai, China) exclusive rights to develop and commercialize ovarian cancer candidate niraparib ( MK-4827) in Greater China, including Hong Kong and Macau. Zai also granted Tesaro an option to license ex-Chinese rights to two of Zai's discovery stage immuno-oncology programs.

Tesaro will receive $15 million up front and is eligible for undisclosed development and commercialization milestones, plus tiered royalties. Tesaro also retained an option to co-promote niraparib in Greater China. ...